{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:48:52Z","timestamp":1770986932695,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T00:00:00Z","timestamp":1426291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40265-015-0371-4","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T15:37:11Z","timestamp":1426261031000},"page":"665-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"75","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,14]]},"reference":[{"key":"371_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. http:\/\/www.goldcopd.org\/guidelines-global-strategy-for-diagnosis-management.html . Accessed 24 Feb 2015."},{"key":"371_CR2","unstructured":"World Health Organization. Chronic obstructive pulmonary disease (COPD): fact sheet no 315. 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs315\/en\/#. Accessed 24 Feb 2015."},{"issue":"1","key":"371_CR3","first-page":"235","volume":"5","author":"AJ Guarascio","year":"2013","unstructured":"Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5(1):235\u201345.","journal-title":"Clinicoecon Outcomes Res."},{"key":"371_CR4","unstructured":"Boehringer Ingelheim International GmbH. Striverdi respimat (olodaterol) inhalation spray for oral inhalation: US prescribing information. 2014. http:\/\/www.accessdata.fda.gov . Accessed 24 Feb 2015."},{"key":"371_CR5","unstructured":"Boehringer Ingelheim International GmbH. Striverdi Respimat 2.5\u00a0microgram, solution for inhalation: EU summary of product characteristics. 2013. http:\/\/mri.medagencies.org\/Human . Accessed 24 Feb 2015."},{"issue":"1","key":"371_CR6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.110.167007","volume":"334","author":"T Bouyssou","year":"2010","unstructured":"Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53\u201362.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"371_CR7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.111.179259","volume":"337","author":"P Casarosa","year":"2011","unstructured":"Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600\u20139.","journal-title":"J Pharmacol Exp Ther."},{"key":"371_CR8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/2193-1801-3-419","volume":"3","author":"GJ Feldman","year":"2014","unstructured":"Feldman GJ, Bernstein JA, Hamilton A, et al. The 24-h FEV1 time profile of olodaterol once daily via Respimat\u00ae and formoterol twice daily via Aerolizer\u00ae in patients with GOLD 2\u20134 COPD: results from two 6-week crossover studies. Springerplus. 2014;3:419.","journal-title":"Springerplus."},{"key":"371_CR9","doi-asserted-by":"crossref","unstructured":"Lange P, Aumann J-L, Hamilton A, et al. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Resp Med. 2014;4(4). doi: 10.4172\/2161-105X.1000196 .","DOI":"10.4172\/2161-105X.1000196"},{"key":"371_CR10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/COPD.S61717","volume":"9","author":"GT Ferguson","year":"2014","unstructured":"Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat\u00ae in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629\u201345.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"371_CR11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/COPD.S62502","volume":"9","author":"A Koch","year":"2014","unstructured":"Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat\u00ae versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697\u2013714.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"issue":"6","key":"371_CR12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.pupt.2011.07.006","volume":"24","author":"JA Noord van","year":"2011","unstructured":"van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel \u03b22-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666\u201372.","journal-title":"Pulm Pharmacol Ther."},{"key":"371_CR13","first-page":"A6183","volume":"179","author":"JA Noord van","year":"2009","unstructured":"van Noord JA, Korducki L, Hamilton AL. Four weeks once daily treatment with BI 1744 CL, a novel long-acting beta-2- agonist, is effective in COPD patients [abstract no. 210]. Am J Resp Crit Care Med. 2009;179:A6183.","journal-title":"Am J Resp Crit Care Med."},{"key":"371_CR14","doi-asserted-by":"crossref","unstructured":"Ichinose M, Takizawa A, Izumoto T, et al. Efficacy of 4 weeks\u2019 once-daily treatment with olodaterol (BI 1744), a novel long-acting B2-agonist, in Japanese patients with COPD [abstract no. A2931]. Am J Respir Crit Care Med. 2012;185 (meeting abstracts).","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2931"},{"key":"371_CR15","doi-asserted-by":"crossref","unstructured":"Joos G, Aumann JL, Coeck C, et al. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting B2-agonist, in patients with COPD [abstract no. A2930]. Am J Respir Crit Care Med. 2012;185 (meeting abstracts).","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2930"},{"key":"371_CR16","unstructured":"Brown SM, Barnes PJ, Donnelly LE. Effect of olodaterol on the relaxation of small airways [abstract]. In: Annual Congress of the European Respiratory Society; 2011."},{"key":"371_CR17","first-page":"A2603","volume":"187","author":"J Troost","year":"2013","unstructured":"Troost J, Pivovarova A, Kunz C. Evaluation of the effects of the long-acting beta2-agonist olodaterol on the Qt and Qtc interval in healthy subjects [abstract no. B24]. Am J Resp Crit Care Med. 2013;187:A2603.","journal-title":"Am J Resp Crit Care Med."},{"key":"371_CR18","doi-asserted-by":"crossref","unstructured":"Maltais F, Kirsten A-M, Hamilton AL, et al. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies [abstract]. Chest. 2013;144(4_meeting abstracts):748A.","DOI":"10.1378\/chest.1701949"},{"key":"371_CR19","doi-asserted-by":"crossref","unstructured":"Ferguson G, Sachs P, Hamilton A, et al. Efficacy of olodaterol once daily (QD) via Respimat in GOLD 2\/3 COPD patients not receiving background therapy: pooled data from 48-week studies [abstract]. Chest. 2013;144(4_meetingabstracts):727A.","DOI":"10.1378\/chest.1702133"},{"issue":"6","key":"371_CR20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","volume":"85","author":"DA Mahler","year":"1984","unstructured":"Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751\u20138.","journal-title":"Chest."},{"key":"371_CR21","doi-asserted-by":"crossref","unstructured":"Niewoehner D, McGarvey L, Hamilton AL, et al. Pooled safety analysis of olodaterol once daily via Respimat\u00ae versus placebo and formoterol twice daily in patients with COPD: independently adjudicated respiratory-related serious adverse events [abstract]. Chest. 2013;144(4_meeting abstracts):712A.","DOI":"10.1378\/chest.1701665"},{"key":"371_CR22","doi-asserted-by":"crossref","unstructured":"McGarvey L, Niewoehner D, Magder S, et al. One-year safety of olodaterol once daily via Respimat\u00ae in patients with GOLD 2\u20134 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD. 2015. doi: 10.3109\/15412555.2014.991864 .","DOI":"10.3109\/15412555.2014.991864"},{"issue":"3","key":"371_CR23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","volume":"105","author":"EL Toy","year":"2011","unstructured":"Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435\u201341.","journal-title":"Respir Med."},{"issue":"8","key":"371_CR24","doi-asserted-by":"crossref","first-page":"e70784","DOI":"10.1371\/journal.pone.0070784","volume":"8","author":"VC Chung","year":"2013","unstructured":"Chung VC, Ma PH, Hui DS, et al. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One. 2013;8(8):e70784.","journal-title":"PLoS One."},{"key":"371_CR25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2147\/COPD.S59673","volume":"9","author":"NS Roskell","year":"2014","unstructured":"Roskell NS, Anzueto A, Hamilton A, et al. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J COPD. 2014;9:813\u201324.","journal-title":"Int J COPD."},{"key":"371_CR26","doi-asserted-by":"crossref","unstructured":"Buhl R, Derom E, Ferguson G, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies [abstract no. 1895]. In: 24th Annual Congress of the European Respiratory Society; 2014.","DOI":"10.1055\/s-0035-1544637"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0371-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0371-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0371-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T23:52:03Z","timestamp":1566431523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0371-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,14]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["371"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0371-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,14]]}}}